1. Home
  2. ENTA vs AGD Comparison

ENTA vs AGD Comparison

Compare ENTA & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.16

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo abrdn Global Dynamic Dividend Fund of Beneficial Interest

AGD

abrdn Global Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$12.49

Market Cap

318.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
AGD
Founded
1995
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
318.4M
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
ENTA
AGD
Price
$13.16
$12.49
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
199.8K
95.5K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$5.88
$10.25
52 Week High
$17.15
$13.98

Technical Indicators

Market Signals
Indicator
ENTA
AGD
Relative Strength Index (RSI) 41.92 57.56
Support Level $13.00 $12.19
Resistance Level $13.76 $12.83
Average True Range (ATR) 0.72 0.21
MACD -0.13 -0.02
Stochastic Oscillator 8.71 63.53

Price Performance

Historical Comparison
ENTA
AGD

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.

Share on Social Networks: